阿替利珠单抗治疗化疗进展后晚期非小细胞肺癌的成本效用分析*
张川,冉凤林,顾凌寒,刘悦,田攀文,李为民
Cost-utility Analysis of Atezolizumab in the Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer
ZHANG Chuan,RAN Fenglin,GU Linghan,LIU Yue,TIAN Panwen,LI Weimin
医药导报
.
2022, (12): 1854
-1859
.
DOI: 10.3870/j.issn.1004-0781.2022.12.023